



PATENT ATTORNEY DOCKET NO. 045636-5037

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Guy SERRE et al.	
Application No.: Unassigned)	Group Art Unit: Unassigned
Date of National Stage Entry: June 30, 2000)	Examiner: Unassigned
Based on: PCT/FR98/02899)	Examiner. Onassigned
Filed: December 29, 1998)	RECEIVED
For: PEPTIDE EPITOPES RECOGNIZED BY) ANTI-FILAGGRIN AUTO-ANTIBODIES)	JUN 2 4 2002
IN SERUM FROM RHEUMATOID ARTHRITIS PATIENTS)	TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed within three months of the date of the National Stage entry of the above-referenced application. Accordingly, Applicants do not believe that a fee is due for filing this paper.

A copy of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

An International Search Report, citing the documents and setting forth the relevance thereof are also enclosed for the Examiner's consideration. In addition to this citation the relevance of French language document WO 98/08946 is noted on page 4, lines 21-32, of the specification, which cites the French priority document of this publication.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents do constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR

EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Elizabeth C. Weimar

Reg. No. 44.478

Dated: June 30, 2000

MORGAN, LEWIS & BOCKIUS LLP 1800 M Street, N.W. Washington, D.C. 20036-5869 (202) 467-7000



INFORMATION DISCLOSURE CITATION		Attorney Docket No. 045636-5037		Application No.: Unassigned			
(Use	several sheets if necessar	у)	Applicants: Guy SERRE	et al. PAC	GE 1 of 1		
PTO Form 1449		Filing Date: June 30, 2000		Group Art Unit: Unassigned			
		U.S. PAT	TENT DOCUMENTS				
*Examiner Initial	Document Number	Date	Name /	Class	Sub Class Filing Date		g Date
		7					,
		1,0					
		FOREIGN	PATENT DOCUMENTS				
	Document Number	Date	Country	Class	Sub Class	Tran YES	slation NO
-	WO 98 08946	03/5/199,8	WIPO				
			·				
	OTHER DOCU	MENTS (Includi	ng Author, Title, Date, Per	tinent Page	es, Etc.)		
	autoantiboides are po	osttranslationally	opes targeted by the rheuman generated on various sites on ol. 162, no. 1, 1 January 19	f (Pro)filag	ggrin by deimina		ginine
	G. A. Schellekens et al., "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific antibodies", <u>J. Clin. Invest.</u> , vol. 101, no. 1, 1 January 1998, abstract						
	G. A. Schellekens et Recognized by Auto 40, no. 9, Suppl. 08	antibodies In Sera	ied Arginine Residue Citrul a From Rheumatoid Arthriti 997, abstract.	lines Is The Patients"	e Major Constitu , Arthritis and F	ient Of Ep Cheumatis	oitopes m , vol.
Examiner			Date Considered			. —	
			not citation is in conformand Include copy of this form w				h citation

RECEIVED RECEIVED

JUN 2 4 27 JUN 2 4 2002

TECH CENTER 1600/2900

WA01A/156768.1 January 16. 1998